The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The more diversification a biotech can have the better for me, so Avacta's dual business model should be seem as a huge positive imo. I usually avoid this sector as constant dilution and the timeframes involved make it it extremely difficult for small biotech's to thrive...….especially in Europe.
The 2 biggest reasons I have gone in big with Avacta is the fact it has a diagnostics division to help alleviate those dilution/funding concerns, as well its Precision platform just looking to improve the therapeutic potential of already approved drugs...…. a much safer option than new drug entities imo.
I would prefer Avacta to remain a dual play to be honest, especially with Covid testing being required for many many years.
https://avacta.com/therapeutics/pipeline/
Been updated today with AVA3996 now added and close to being ready for Phase 1 trials it seems........more clues AVA6000 data is looking positive??
https://www.linkedin.com/in/adrian-ruskin-fcilt-71895083/
Adrian Ruskin (FCILT)
Director Of Operations
"Experienced Supply Chain, Operations,Logistics and Customer Services Director with a demonstrated history of working in the medical device (volume manufacturing and start-up) and military aerospace industry.
Management and budgetary ownership of all sourcing, planning, implementation, CMO management, customer service, device installation, servicing and maintenance, operations management, distribution and warehousing internationally, with responsibility for teams of upto 120 personnel.
I have been heavily involved in ERP selection and implementations (SAP) including barcoding"
https://www.linkedin.com/posts/mirnax-biosens-sl_escv-activity-6851566589175758848-zRft/
Happy to announce that our scientific team poster's had obtained a Mention Award during the 23rd Annual Conference of the #ESCV for their contribution to the state-of-the-art of SARS-CoV2 diagnostic.
Thanks to all collaborators, specially Avacta & Hospital Carlos III
There’s another significant point I would make about the LG announcement.
One area that I was concerned about with Affimers was there half-life properties. Being so small, whilst great for tissue penetration, ultimately means they get cleared through the kidneys too quickly. Affimer XT removes that concern for me and allows the Affimer platform to have antibody half-life properties if needed - a major de-risking point for me.
Stuck a few thoughts on Twitter if anybody is interested....
https://twitter.com/lee_williams97/status/1445311510935396353
Needless to say I'm feeling hugely positive about where Avacta is at right now, especially in its Therapeutics division!
Added with Al’s positive comments, this is the biggest clue that AVA6000 data is looking really positive. After all the chief investigator is based at Leeds, so if he’s happy with the data then it speaks volumes imo.
The massive chemotherapy market is potentially about to be disrupted by little old Avacta.
https://twitter.com/AstreaBio/status/1438574432419733508
Pursuant to the December 2020 license agreement with AVACTA, we have also dedicated new laboratory space for Affimer® ligand discovery and development work.
So the Precision tech is working in pre-clinical models with AVA6000, AVA3996, 2 TMAC’s and Points Canseek. I appreciate these are animal models and nothing is guaranteed, but when such amazing results are repeated over so many programs, it surely increases the chances of success in humans dramatically? This is what is attracting all this top talent to Avacta, which lets be honest is still early stage. I can’t see a situation where Avacta can remain independent if AVA6000 if successful, far too much potential for large pharma to turn a blind eye.
https://avacta.com/lateral-flow-assay-testing-for-covid-19-tackling-asymptomatic-spread/
https://www.linkedin.com/in/neilbell/
Looks like Neil Bell had a big hand in locating new Avacta's offices in White City, home to his former employer Autolus.
A NEW HOME FOR MULTI-DISCIPLINARY RESEARCH
White City Campus will be a multi-disciplinary research hub like few others. The Molecular Sciences Research Hub (MSRH) means, for the first time, 800 scientists, clinicians, engineers and commercial partners will be together under one roof to advance science in areas like clean energy, chemical biology and healthcare. Next door, the Sir Michael Uren Hub combines the latest in medical research and engineering to improve the treatment and diagnosis of diverse medical conditions. While global corporations including Novartis, Autolus and Synthace are catalysing a life sciences cluster at White City, too.
validation study available
Delta variant validation was conducted at an external site, using samples obtained from patients whose symptoms were consistent with the Delta variant, and subsequently verified as Delta variant by PCR prior to testing the samples on the lateral flow devices. Read more in the announcement HERE or download a copy of the validation study HERE.
Avacta been tagged in following post from the NHC. The National Horizons Centre (NHC) is Teesside University's £22.3m centre of excellence for the global biosciences and healthcare sector, located in Darlington.
https://www.linkedin.com/posts/dr-jen-vanderhoven_diagnostic-discovery-development-activity-6842027000358543360-awKF
Coming soon, the National Horizons Centre's trailblazing new continuing professional development training course...
*** Next-generation diagnostics: discovery, development, evaluation and integration ***
November 2021 at the National Horizons Centre.
This three-day course covers all aspects of #diagnostic methods used in clinical medicine - spanning #discovery, #development, #evaluation and integration into mainstream #medicine. Including #genomic, #proteomic and #histologic methods, and approaches from laboratory-based to wearable technologies, the course combines lectures from experts and hands-on practical classes. Delegates will learn about requirements for integration into mainstream medicine including how to generate key data used to demonstrate accuracy and about processes for obtaining approval in the UK and overseas.
Contact us know for more information https://lnkd.in/dHHkSFZ
#genetherapy #research #training #nhs #innovation #strategy #diagnostics #cancertreatment #biotechnology #healthcare #science
Peter Simpson Nicola Heron Lee Beniston Harry J. Barraza Julian Braybrook Bionow MediCity UK BioCity Alicia Greated KTN NEPIC Avacta Will Dracup Arun Harish NHS England NHSX Northern Cancer Foundation Sam Whitehouse Andy Jones Sarah Goulding
John S. Young Professor Vikki Rand Alex Newman Muhammad Safwan Akram Cancer Research UK (CRUK) Medicines Discovery Catapult Cell and Gene Therapy Catapult BBSRC MRC Laboratory of Molecular Biology (LMB) EPSRC Innovate UK Department for Business, Energy and Industrial Strategy (BEIS) Academic Health Science Network for the North East and North Cumbria (AHSN NENC) The NP11Nathalie Huther, PhD, MRSC Nathalie Carter BA, MSc, FCMI QuantuMDx Group Limited Illumina
https://www.linkedin.com/posts/kkomanduri_avacta-announces-new-appointments-to-the-activity-6841774689329799168-Ag9H/
"I’m thrilled to join the Scientific Advisory Board of Avacta Therapeutics which has an exciting pipeline of technologies for novel oncology therapies"
#oncology #cancer #biotech
Point actually have clinical trials going on in the UK at present. I’m sure some representatives from Point and Avacta will have been touching base.
It’s a great deal with a point as not only can put prodrugs through the clinic, but they can also licence the tech out themselves, with Avacta and Tufts picking up a percentage of the licensing revenue.